List of Remodulin drug patents
Remodulin is owned by United Therap.
Remodulin contains Treprostinil.
Remodulin has a total of 9 drug patents out of which 0 drug patents have expired.
Remodulin was authorised for market use on 21 May, 2002.
Remodulin is available in injectable;iv (infusion), subcutaneous dosage forms.
Remodulin can be used as administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration, a method of treating a human patient suffering from pulmonary hypertension, a method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer, administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration.
The generics of Remodulin are possible to be released after 29 March, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 3 months from now) | |
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(1 year, 10 months from now) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(1 year, 10 months from now) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(1 year, 10 months from now) | |
| US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(5 years from now) | |
| US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(5 years from now) | |
| US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(6 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 21 May, 2002
Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic